Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2021.01.091 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2021.01.091 33571909!7846235!33571909     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biochem+Biophys+Res+Commun 2021 ; 545 (ä): 203-207 Nephropedia Template TP {{tp|p=33571909|t=2021. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro |pdf=|usr=}}{{33571909}} gab.com Text 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33571909 #FOAvip The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19. Twit Text FOAVip 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33571909 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33571909 #FOAvip English Wikipedia <ref>{{Cite pmid|33571909}}</ref> 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro #MMPMID33571909 Sakurai Y; Ngwe Tun MM; Kurosaki Y; Sakura T; Inaoka DK; Fujine K; Kita K; Morita K; Yasuda J Biochem Biophys Res Commun 2021[Mar]; 545 (ä): 203-207 PMID33571909show ga The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19. |*COVID-19 Drug Treatment[MESH] |Aminolevulinic Acid[MESH] |Animals[MESH] |Antiviral Agents/administration & dosage/*pharmacology[MESH] |COVID-19/prevention & control/virology[MESH] |Caco-2 Cells[MESH] |Chlorocebus aethiops[MESH] |Citric Acid[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Evaluation, Preclinical/methods[MESH] |Ferrous Compounds/pharmacology[MESH] |Humans[MESH] |Levulinic Acids/administration & dosage/*pharmacology[MESH]5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro (epmc).pdf DeepDyve Pubget Overpricing